{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-11.1","upperLimit":"-2.3","value":"-6.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"53"}],"units":"Participants"}],"title":"Change at Day 7"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-3.8","upperLimit":"5","value":"0.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"53"}],"units":"Participants"}],"title":"Change at Day 28"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-2.3","upperLimit":"6.7","value":"2.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"51"}],"units":"Participants"}],"title":"Change at Day 56"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.7","upperLimit":"9.9","value":"5.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"46"}],"units":"Participants"}],"title":"Change at Day 78"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-2.6","upperLimit":"6.4","value":"1.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"}],"units":"Participants"}],"title":"Change at Day 100"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.6","upperLimit":"11.3","value":"6.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"}],"units":"Participants"}],"title":"Change at Day 128"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-0.2","upperLimit":"9.8","value":"4.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"}],"units":"Participants"}],"title":"Change at Day 156"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.2","upperLimit":"10.9","value":"6.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"}],"units":"Participants"}],"title":"Change at Day 184"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.5","upperLimit":"14.7","value":"9.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"title":"Change at Day 212"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.9","upperLimit":"16.2","value":"11"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"}],"units":"Participants"}],"title":"Change at Day 240"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.3","upperLimit":"12.2","value":"7.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"}],"units":"Participants"}],"title":"Change at Day 268"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.8","upperLimit":"15.2","value":"10"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"}],"units":"Participants"}],"title":"Change at Day 296"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.9","upperLimit":"18.9","value":"11.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"}],"units":"Participants"}],"title":"Change at Day 324"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.8","upperLimit":"19.7","value":"10.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"title":"Change at Day 352"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-19.1","upperLimit":"15.1","value":"-2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"title":"Change at Day 380"}],"denoms":[{"counts":[{"groupId":"OG000","value":"53"}],"units":"Participants"}],"description":"EQ-5D-5L was a 5-item questionnaire consisted of 2 components: a health state profile/a single utility index value and an optional VAS. EQ-5D health state profile/a single utility index value had 5 dimensions including mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension had 5 response levels: 1 =no problems, 2 =slight problems, 3 =moderate problems, 4 =severe problems and 5 =extreme problems. The scores for the 5 dimensions were used to compute a single utility score ranging from 0 to 1 representing the general health status of the individual. Higher score indicated better health status. EQ-5D VAS was used to record participant's rating for his/her \"health today\" and ranging from 0 to 100, where 0 =worst imaginable health state and 100 = best imaginable health state.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received a conditioning regimen of cyclophosphamide 300 mg/m\\^2 IV infusion and fludarabine 30 mg/m\\^2 IV infusion daily for 3 days from Day -5 to Day -3. On Day 1, participants received recommended phase 2 dose (RP2D) dose of JNJ-68284528 0.75\\*10\\^6 CAR positive viable T cells/kg as IV infusion.","id":"OG000","title":"Phase 2 (US Population)"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"mITT analysis Set included all participants who received a JNJ-68284528 infusion at the targeted RP2D dose level. Here, N (number of participants analyzed) signifies participants who were evaluable for this outcome measure and \"n\" (number analyzed) signifies those participants who were evaluable for specified time points.","reportingStatus":"POSTED","timeFrame":"Baseline, Days 7, 28, 56, 78, 100, 128, 156, 184, 212, 240, 268, 296, 324, 352 and 380","title":"Phase 2 (US Population): Change From Baseline in EuroQol Five Dimension Questionnaire (EQ-5D-5L) Visual Analogue Scale (VAS) Score at Days 7, 28, 56, 78, 100, 128, 156, 184, 212, 240, 268, 296, 324, 352 and 380","type":"SECONDARY","unitOfMeasure":"Score on a scale"}